Indication
Small Cell Neuroendocrine Carcinoma
2 clinical trials
4 products
1 drug
Clinical trial
A Phase 2 Study of Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2024-03-31
Product
ApalutamideProduct
CetrelimabClinical trial
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine CarcinomasStatus: Active (not recruiting), Estimated PCD: 2024-10-01
Product
CabozantinibProduct
IpilimumabDrug
T-VEC